FDA Approves Merck's Vioxx, Creating Arthritis Market Battle with Monsanto's Celebrex

Strategic Insights -

The Food and Drug Administration (FDA) has approved Merck & Co.'s new arthritis drug, Vioxx, which is expected to reach pharmacies in mid-June. Vioxx is a COX-2 inhibitor, a new class of drugs that offer the same pain relief as traditional arthritis medications but with fewer side effects, particularly ulcers and intestinal bleeding. This approval marks a significant development in the arthritis market, as Vioxx will now compete directly with Monsanto's Celebrex, which has been on the U.S. market since mid-January. Celebrex has generated 4 million prescriptions since its launch, and both drugs are expected to benefit from the growing market for arthritis treatments.

Key Takeaways:

  • The FDA approved Vioxx, a COX-2 inhibitor, for the treatment of arthritis, menstrual pain, and acute pain in adults.
  • Vioxx is expected to reach pharmacies in mid-June, while Celebrex has been on the market since mid-January and has generated 4 million prescriptions.
  • Both Vioxx and Celebrex offer similar pain relief to traditional arthritis medications but with fewer side effects.
  • Merck has priced Vioxx at $2.02 per pill, the same price as Celebrex for a once-a-day dosage.
  • The FDA has ordered both Merck and Monsanto to include standard warnings on their labels regarding gastrointestinal problems.
  • The FDA may remove the standard warning label for Vioxx and/or Celebrex if further tests demonstrate their safety profile against NSAIDs.
  • Merck won a marketing edge due to Vioxx's approval for additional indications, including menstrual pain and acute pain in adults.
  • Monsanto's biggest advantage is that Celebrex was first on the market, while Merck's biggest advantage is its competitively priced Vioxx.

Statistics:

  • 4 million prescriptions for Celebrex have been written since its launch in mid-January.
  • Vioxx and Celebrex are priced at $2.02 per pill for a once-a-day dosage.
  • Merck's stock fell 94 cents to $71.31 a share, while Monsanto's stock fell 12.5 cents to $44.38 following the FDA's approval of Vioxx.

Sources:

  • "Food and Drug Administration" (no date cited, original text)
  • "Merck & Co." (no date cited, original text)
  • "Monsanto Co." (no date cited, original text)
  • Edward Jones brokerage (no date cited, original text)
  • William Fiala, quoted in the original text (no date cited)